Related Experiment Video

Updated: Mar 24, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

13.1K

The Therapeutic Potential of Targeting TL1A in a Spectrum of Inflammatory Disorders

Konstantina Kitsou1, Georgios Kokkotis2, Giorgos Bamias2

  • 1National and Kapodistrian University of Athens, Athens, Greece.

Journal of Inflammation Research
|March 23, 2026
PubMed

Insights

Tumor Necrosis Factor (TNF)-like cytokine 1A (TL1A) plays a key role in immune responses and inflammatory diseases like Inflammatory Bowel Disease (IBD). Targeting the TL1A/DR3 pathway with therapies shows promise for treating IBD and other immune-mediated conditions.

Area of Science:

  • Immunology
  • Molecular Biology
  • Gastroenterology

Background:

  • Tumor Necrosis Factor (TNF)-like cytokine 1A (TL1A) is a TNFSF member that binds to Death Domain Receptor 3 (DR3) and Decoy Receptor 3 (DcR3).
  • TL1A/DR3 signaling influences adaptive immunity, mucosal homeostasis, and fibrosis, implicating it in inflammatory and autoimmune diseases.
  • The TL1A/DR3 system is particularly relevant in the pathogenesis of Inflammatory Bowel Disease (IBD) and allergic lung inflammation.

Purpose of the Study:

  • To elucidate the immunological functions of the TL1A/DR3 system.
  • To connect TL1A/DR3 pathway's role in the pathogenesis of IBD and other immune-mediated conditions.
  • To review the therapeutic potential of targeting the TL1A/DR3 pathway, including anti-TL1A monoclonal antibodies.

Main Methods:

  • Narrative review of existing literature.
  • Analysis of mechanistic evidence from animal models.
  • Examination of associations with human disease states.

Main Results:

  • The TL1A/DR3 system is implicated in the pathogenesis of IBD and allergic lung inflammation.
  • Clinical trials with anti-TL1A monoclonal antibodies in IBD patients show positive clinical and endoscopic outcomes with a favorable safety profile.
  • The TL1A/DR3 pathway represents a potential novel therapeutic target.

Conclusions:

  • The TL1A/DR3 pathway is a critical regulator of immune responses and is involved in inflammatory and autoimmune diseases.
  • Targeting TL1A with monoclonal antibodies is a promising therapeutic strategy for IBD.
  • Further research is needed to address challenges and fully realize the therapeutic potential of targeting the TL1A/DR3 pathway.
Keywords:
DR3TL1ATNFSF15autoimmunityinflammation

More Related Videos

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

8.1K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
725
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
18.4K